Peter F.A. Mulders

5.9k total citations
43 papers, 1.9k citations indexed

About

Peter F.A. Mulders is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Peter F.A. Mulders has authored 43 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 13 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Oncology. Recurrent topics in Peter F.A. Mulders's work include Prostate Cancer Treatment and Research (31 papers), Prostate Cancer Diagnosis and Treatment (21 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Peter F.A. Mulders is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Prostate Cancer Diagnosis and Treatment (21 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). Peter F.A. Mulders collaborates with scholars based in Netherlands, Belgium and France. Peter F.A. Mulders's co-authors include Jack A. Schalken, Daphne Hessels, Martijn P.M.Q. van Gils, Sander A. Jannink, Erik B. Cornel, Christina A. Hulsbergen‐van de Kaa, Inge M. van Oort, Frank Smit, Hendrik Van Poppel and H. Vergunst and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Peter F.A. Mulders

43 papers receiving 1.9k citations

Peers

Countries citing papers authored by Peter F.A. Mulders

Since Specialization

Citations

This map shows the geographic impact of Peter F.A. Mulders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter F.A. Mulders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter F.A. Mulders more than expected).

Fields of papers citing papers by Peter F.A. Mulders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter F.A. Mulders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter F.A. Mulders. The network helps show where Peter F.A. Mulders may publish in the future.

Co-authorship network of co-authors of Peter F.A. Mulders

This figure shows the co-authorship network connecting the top 25 collaborators of Peter F.A. Mulders. A scholar is included among the top collaborators of Peter F.A. Mulders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter F.A. Mulders. Peter F.A. Mulders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of complications and biochemical recurrence rates after (super) extended lymph node dissection during radical prostatectomy 2024 ·World Journal of Urology ·(unknown), Bas Israël, (unknown), (unknown), (unknown), Heidi V.N. Küsters‐Vandevelde, Peter F.A. Mulders, J.P. Michiel Sedelaar, Diederik M. Somford, Jean‐Paul A. van Basten	1
2	Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer 2022 ·Prostate Cancer and Prostatic Diseases ·(unknown), Hans de Jong, Sandra Steyaert, Willem J. G. Melchers, Peter F.A. Mulders, Jack A. Schalken	12
3	Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer – A multicenter population-based cohort study 2021 ·Clinical Nutrition ·(unknown), J.P. Michiel Sedelaar, Peter F.A. Mulders, Katja K.H. Aben, Lambertus A. Kiemeney, Alina Vrieling	20
4	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial 2018 ·European Urology Focus ·Peter F.A. Mulders, Luis Martínez‐Piñeiro, Axel Heidenreich, Marko Babjuk, Marc Colombel, Renzo Colombo, Piotr Radziszewski, (unknown), C. Surcel, (unknown), J. Alfred Witjes, Christien Caris, Raymond G. Schipper, Wim P.J. Witjes	3
5	Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone 2017 ·Clinical Genitourinary Cancer ·Charles J. Ryan, Thian Kheoh, Jinhui Li, Arturo Molina, Peter De Porre, Joan Carles, Eleni Efstathiou, Philip W. Kantoff, Peter F.A. Mulders, Fred Saad, Kim N.	23
6	Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 2017 ·European Urology ·Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Johann S. de Bono, Eric J. Small, Neal D. Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Peter De Porre, Mary B. Todd, Margaret K. Yu, Charles J. Ryan	26
7	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide 2016 ·Clinical Pharmacokinetics ·(unknown), Rianne J. Hendriks, Peter F.A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp	72
8	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 2016 ·European Urology ·Johann S. de Bono, Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric J. Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian Kheoh, Jinhui Li, Mary B. Todd, Charles J. Ryan, Thomas W. Flaig	55
9	Better survival of renal cell carcinoma in patients with inflammatory bowel disease 2015 ·Oncotarget ·Lauranne Derikx, (unknown), Loes H.C. Nissen, Joost P.H. Drenth, Carla M. van Herpen, Wietske Kievit, Rob H.A. Verhoeven, Peter F.A. Mulders, Christina A. Hulsbergen‐van de Kaa, Marye J. Boers‐Sonderen, Tim van den Heuvel, Marieke Pierik, Irıs D. Nagtegaal, Frank Hoentjen	9
10	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies 2015 ·European Urology ·Joaquim Bellmunt, Thian Kheoh, Margaret K. Yu, Matthew R. Smith, Eric J. Small, Peter F.A. Mulders, Karim Fizazi, Dana E. Rathkopf, Fred Saad, Howard I. Scher, Mary‐Ellen Taplin, Ian D. Davis, Dirk Schrijvers, Andrew Protheroe, Arturo Molina, Peter De Porre, Thomas W. Griffin, Johann S. de Bono, Charles J. Ryan, Stéphane Oudard	21
11	Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy 2015 ·Cancer Immunology Immunotherapy ·Peter F.A. Mulders, Maria De Santis, Thomas Powles, Karim Fizazi	17
12	The value of magnetic resonance imaging and ultrasonography (MRI/US)‐fusion biopsy platforms in prostate cancer detection: a systematic review 2015 ·British Journal of Urology ·(unknown), (unknown), Harrie P. Beerlage, (unknown), Peter F.A. Mulders, Hessel Wijkstra	79
13	Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer 2013 ·Prostate Cancer and Prostatic Diseases ·Oscar B. Goodman, Thomas W. Flaig, A. Molina, Peter F.A. Mulders, Karim Fizazi, H. Suttmann, (unknown), Thian Kheoh, Johann S. de Bono, Howard I. Scher	79
14	Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis 2012 ·The Prostate ·G. Robert, Sander A. Jannink, Frank Smit, Tilly Aalders, Daphne Hessels, R.G.H.M. Cremers, Peter F.A. Mulders, Jack A. Schalken	42
15	Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer 2012 ·European Urology ·G.H.J.M. Leyten, Daphne Hessels, Sander A. Jannink, Frank Smit, Hans de Jong, Erik B. Cornel, Theo M. de Reijke, H. Vergunst, Paul J.M. Kil, Ben C. Knipscheer, Inge M. van Oort, Peter F.A. Mulders, Christina A. Hulsbergen‐van de Kaa, Jack A. Schalken	268
16	The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? 2010 ·British Journal of Urology ·Guillaume Ploussard, Alexander Haese, Hendrik Van Poppel, Michael Marberger, Arnulf Stenzl, Peter F.A. Mulders, Hartwig Huland, Laurence Bastien, (unknown), Mesut Remzi, Martina Tinzl, Susan Feyerabend, Alexander B. Stillebroer, Martijn P.M.Q. van Gils, Jack A. Schalken, Alexandre de la Taille	46
17	Preliminary evaluation of the effect of dutasteride on PCA3 in post‐DRE urine sediments: A randomized, open‐label, parallel‐group pilot study 2009 ·The Prostate ·Martijn P.M.Q. van Gils, Daphne Hessels, W. P. Peelen, H. Vergunst, Peter F.A. Mulders, Jack A. Schalken	17
18	Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results 2008 ·The Prostate ·Martijn P.M.Q. van Gils, Daphne Hessels, Christina A. Hulsbergen‐van de Kaa, J. Alfred Witjes, Cornelius F.J. Jansen, Peter F.A. Mulders, Harry G. Rittenhouse, Jack A. Schalken	61
19	Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy 2008 ·European Urology ·Alexander Haese, Alexandre de la Taille, Hendrik Van Poppel, Michael Marberger, Arnulf Stenzl, Peter F.A. Mulders, Hartwig Huland, Clément-Claude Abbou, Mesut Remzi, Martina Tinzl, Susan Feyerabend, Alexander B. Stillebroer, Martijn P.M.Q. van Gils, Jack A. Schalken	332
20	Molecular PCA3 diagnostics on prostatic fluid 2007 ·The Prostate ·Martijn P.M.Q. van Gils, Erik B. Cornel, Daphne Hessels, W. P. Peelen, J. Alfred Witjes, Peter F.A. Mulders, Harry G. Rittenhouse, Jack A. Schalken	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact